BackInstitute of Biomedical Research Overview

Institute of Biomedical Research Total Liabilities

Latest total liabilities for MRES: $640K.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$641457.00
↓ 2.47% YoYΔ $-16271.00 vs prior year quarter

Peer trimmed avg / median

Loading

Institute of Biomedical Research Total Liabilities History

Loading

Institute of Biomedical Research vs. peers: Total Liabilities Comparison

Loading

Institute of Biomedical Research Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Institute of Biomedical Research (MRES) FAQ

As of the most recent data (June 2026), MRES shows a total liabilities of $640K. That compares with $660K in the prior-year period — down 2.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MRES's total liabilities is now $640K (was $660K) — a 2.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Institute of Biomedical Research is outperforming or lagging.

Tracking MRES's total liabilities over time shows whether Institute of Biomedical Research is scaling, shrinking, or reshaping that part of the business. The current reading is $640K That compares with $660K in the prior-year period — down 2.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Institute of Biomedical Research's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $640K) with ownership activity and broader fundamentals.

Institute of Biomedical Research's total liabilities is $640K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.